Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (RNAC)
Filing Type: Form 8-K (Current Report)
Report Date: March 9, 2026
Reporting Period: Full year ended December 31, 2025
This filing serves as a notification that the Company announced its financial results for the fiscal year 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this filing.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of 2025 results but does not include specific management commentary, forward-looking guidance, or risk factors within the text provided.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for 2025.
- Verify the Company's cash runway and burn rate based on the full press release details.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the Company remains an emerging growth company and its election status regarding extended transition periods.